Aclaris Initiates Phase 1b Trial for ATI-052 in Atopic Dermatitis

Aclaris Therapeutics has initiated a Phase 1b proof-of-concept trial for ATI-052, an investigational bispecific anti-TSLP/IL-4Rα antibody, in atopic dermatitis. The trial aims to demonstrate the safety and efficacy of ATI-052 in treating AD. The company expects to initiate a second Phase 1b trial in asthma this quarter. The trial follows positive Phase 1a interim results, which showed a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics.